|
FY2025
12 months to Dec 31, 2025
|
FY2024
12 months to Dec 31, 2024
|
FY2023
12 months to Dec 31, 2023
|
FY2022
12 months to Dec 31, 2022
|
FY2021
12 months to Dec 31, 2021
|
|
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Gross profit | |||||
| Operating expenses: | |||||
| Research and development | |||||
| Selling and marketing | |||||
| General and administrative | |||||
| Amortization of intangible assets | |||||
| Goodwill impairment loss | |||||
| Total operating expenses | |||||
| Operating loss | |||||
| Interest and other income, net | |||||
| Other income (expenses) | |||||
| Interest income | |||||
| Interest expense | |||||
| Impairment of available-for-sale debt securities | |||||
| Impairment loss | |||||
| Other income, net | |||||
| Total other income, net | |||||
| Loss before income taxes | |||||
| (Benefit from) provision for income taxes | |||||
| (Loss) income before gain on equity-method investments | |||||
| Net loss from consolidated operations | |||||
| Net loss attributable to noncontrolling interests | |||||
| Net loss attributable to Fulgent | |||||
| Net loss per common share attributable to Fulgent: | |||||
| Basic | |||||
| Diluted | |||||
| Weighted average common shares: | |||||
| Basic | |||||
| Diluted | |||||
Loading...